Japanese
version
issued
on |
No. |
Table of contents |
PDF |
| March 23, 2006 |
223 |
- Important Safety Information
(1)Selegiline Hydrochloride
- Revision of PRECAUTIONS (No. 174)
Lornoxicam (and 3 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [272 KB] |
| February 23, 2006 |
222 |
- Drug Guide for Patients
- Revision of PRECAUTIONS (No. 173)
Amoxapine (and 16 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [400 KB] |
| January 26, 2006 |
221 |
- Proper use of theophylline in childhood asthma
- Impact of X-ray CT apparatus etc. on implantable cardiac pacemaker etc.
- Revision of PRECAUTIONS (No. 172)
(1)Ibuprofen (and 13 others)
(2)Electrosurgical unit (ESU) used in for radiofrequency ablation (RFA)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [430 KB] |
| December 22, 2005 |
220 |
- Important Safety Information
(1)Amiodarone Hydrochloride
(2)Carboplatin
(3)Sevoflurane
(4)Whole Human Blood, Blood for Exchange Transfusion, Fresh-Frozen Human Plasma, Concentrated Human Blood Platelet, Concentrated Human Red Blood Cell, Concentrated Frozen-Thawed Human Red Blood Cells, Washed Human Red Blood Cells, Leukocyte Poor Red Blood Cells
(5)Phenytoin, Phenytoin Sodium, Phenytoin / Phenobarbital, Phenytoin / Phenobarbital / Caffeine and Sodium Benzoate
- Revision of PRECAUTIONS (No. 171)
Zopiclone and (12 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [487 KB] |
| November 24, 2005 |
219 |
- Important Safety Information
(1)Barium Sulfate (excepting preparation for CT)
(2)Fludarabine Phosphate
- Revision of PRECAUTIONS (No. 170)
Bepridil Hydrochloride (and 11 others)
- List of products subject to Early Post-marketing Phase Vigilance
<Reference Material>
- Future Perspective of pharmacogenomics
|
Full text [398 KB] |
| October 27, 2005 |
218 |
- Result of post-marketing safety measures for ticlopidine hydrochloride products with Cypher Stent
- Serious skin disorders induced by drugs
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [159 KB] |
| September 29, 2005 |
217 |
- Reports etc. on adverse reactions associated with influenza vaccines in FY2004
- Important Safety Information
(1)Zedoary Powder and Japanese Tangle Powder Preparation
- Revision of PRECAUTIONS (No. 169)
Paroxetine Hydrochloride Hydrate (and 9 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [426 KB] |
| August 25, 2005 |
216 |
- Serious health hazards in the use of bone cement
- Effects on implantable medical devices (cardiac pacemakers and cardioverter defibrillators) by new system mobile phone terminals and RFID devices
- Important Safety Information
(1)Sodium Valproate
(2)Pranoprofen (oral dosage form)
(3)Hochuekkito
- Revision of PRECAUTIONS (No. 168)
Carbamazepine (and 12 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [667 KB] |
| July 27, 2005 |
215 |
- Important Safety Information
(1)Ethionamide
(2)Etodolac
(3)Gemcitabine Hydrochloride
(4)Omeprazole, Omeprazole Sodium
- Revision of PRECAUTIONS (No. 167)
Tiaprofenic Acid (and 17 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [399 KB] |
| June 23, 2005 |
214 |
- Important Safety Information
(1)Alprostadil, Alprostadil Alfadex (20 mg injectable dosage form)
(2)Donepezil Hydrochloride
(3)Leuprorelin Acetate
(4)Lopinavir / Ritonavir
- Revision of PRECAUTIONS (No. 166)
Cabergoline (and 15 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [354 KB] |
| May 26, 2005 |
213 |
- Impact of X-ray CT apparatus on implantable cardiac pacemaker (Medtronic InSync 8040)
- Important Safety Information
(1)Candesartan Cilexetil, Telmisartan, Valsartan, Losartan Potassium
(2)Ceftriaxone Sodium
(3)Adsorbed Diphtheria-Purified Pertussisi-Tetanus Combined Vaccine
(4)Torasemide
(5)Japanese Encephalitis Vaccine
- Revision of PRECAUTIONS (No. 165)
Fradiomycin Sulfate / Methylprednisolone Betamethasone Sodium Phosphate / Fradiomycin Sulfate (ophthalmic ointment) (and 19 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [389 KB] |
| April 27, 2005 |
212 |
- Results of investigation by the Gefitinib review meeting
- Overview of the notifications for self-inspection etc. issued from April 2004 to February 2005
- Request for cooperation in Early Post-marketing Phase Vigilance
|
Full text [433 KB] |
